Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.63 |
| ▸ | RAB9A | P51151 | 5/20 | 0.63 |
| ▸ | NPC1 | O15118 | 4/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.63 |
| ▸ | CDC25B | P30305 | 6/20 | 0.57 |
| ▸ | TP53 | P04637 | 3/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 6/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | SETD7 | Q8WTS6 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 3/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.51 |
| ▸ | THRB | P10828 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1505251 | 0.87 | GSK3B (0.55) | SMN1; SMN2RAB9ANPC1CYP1A2CYP2C9 | |
| SCHEMBL5928256 | 0.86 | RAB9A (0.52) | SMN1; SMN2RAB9ANPC1TP53CYP1A2 | |
| SCHEMBL1357593 | 0.85 | CDC25B (0.62) | SMN1; SMN2RAB9ANPC1KDM4ECDC25B | |
| SCHEMBL7107744 | 0.83 | CDC25B (0.69) | SMN1; SMN2RAB9ANPC1KDM4ECDC25B | |
| SCHEMBL4445717 | 0.82 | TLR8 (0.54) | TP53HPGDPOLB | |
| SCHEMBL28141853 | 0.82 | RAB9A (0.67) | SMN1; SMN2RAB9ANPC1KDM4ECDC25B | |
| SCHEMBL1356910 | 0.81 | KMT2A (0.53) | SMN1; SMN2RAB9ANPC1KDM4ECDC25B | |
| SCHEMBL4107154 | 0.81 | TRPV1 (0.68) | SMN1; SMN2RAB9ANPC1KMT2AALDH1A1 | |
| SCHEMBL1170135 | 0.81 | RAB9A (0.65) | SMN1; SMN2RAB9ANPC1KDM4ECDC25B | |
| SCHEMBL5417221 | 0.81 | SETD7 (0.52) | SMN1; SMN2RAB9ANPC1KDM4ECDC25B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2651888-B1 | N-((1H-indol-3-yl)-alkyl)-4-benzyl)benzamide and N-((1H-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders | UNIV LEUVEN KATH (BE) | 2017-05-17 | — | — | EP | disclosed |
| CN-103261156-B | For treating the noval chemical compound of neurodegenerative disease | 鲁汶天主教大学研究开发部 | 2016-12-28 | — | — | CN | disclosed |
| US-9266832-B2 | Compounds for the treatment of neurodegenerative diseases | Katholieke Universiteit Levun (BE) | 2016-02-23 | — | — | US | disclosed |
| EP-2651888-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | Katholieke Universiteit Leuven K.U. Leuven R&D (BE) | 2013-10-23 | — | — | EP | disclosed |
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | REMYND (BE) | 2013-10-17 | — | — | US | disclosed |
| CN-103261156-A | New compounds for the treatment of neurodegenerative diseases | LEUVEN K U RES & DEV | 2013-08-21 | — | — | CN | disclosed |
| WO-2012080221-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130274260-A1 | NEW COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | SNCA, MAPT, PSEN1 | SMN1; SMN2 12/4885RAB9A 513/4885NPC1 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.